Green Cash Money

BioElectronics Corporation, a development stage company, develops and markets drug-free anti-inflammatory patches. The company’s products include ActiPatch Therapy, a dermal drug-free, painless, and pulsed energy patch with an embedded battery operated microchip that delivers pulsed electromagnetic frequency therapies to accelerate healing of soft tissue injuries. Its technology provides pulsed electromagnetic energy therapy that is used to reduce swelling, relieve pain, and enhance the healing of post-surgical incisions, chronic wounds, and orthopedic conditions. The company has market clearance/approval for its products in the United States, Canada, and Europe. BioElectronics Corporation sells its products to wholesale distributors, and directly to hospitals and clinics. The company was incorporated in 2000 and is headquartered in Frederick, Maryland.

BIEL at 10:05 AM 6/29/2009: Trading 6% above VWAP

American Scientific Resources, Inc. manufactures and distributes medical products and supplies. The company, also known as Ulster Scientific, is based in New Paltz, New York.

ASFX at 9:48 AM 6/12/2009:  Fibonacci buy signal.

Cobalis Corp., a development stage company, engages in the development and commercialization of pharmaceutical products for allergic diseases. Its product includes PreHistin, a phase III clinical trial product candidate for the treatment of atopic allergic diseases, including seasonal and year-round allergies, migraine, dermatitis, food allergies, and asthma. The company was incorporated in 2000 and is based in Irvine, California. On November 19, 2007, the involuntary petition of Cobalis Corp for liquidation under Chapter 7 bankruptcy was converted to voluntary Chapter 11 reorganization. The involuntary petition was filed on August 1, 2007.

CLSC at 10:14 AM 6/9/2009:  Trading 22% above VWAP

Cancer Therapeutics, Inc. engages in the production and provision of treatments for cancer grouped under the category of biotherapy. The company offers biotherapy services, such as tumor specimen storage, cellular therapies, and patient-specific vaccines. Its services include Cryobank, a process in which a patient’s tumor tissue is removed and stored in a living condition in liquid nitrogen for future use; tumor derived activated cells, a process in which a patient’s tumor is shipped to the laboratory and the cancer-fighting white blood cells that a patient’s immune system has produced to attack that specific cancer are recovered; and vaccines, a process in which a patient’s own cancer cells are grown in a laboratory and are used to develop a patient-specific vaccine. Cancer Therapeutics was founded in 1991 and is based in South Jordan, Utah

CTHP at 9:46 AM 6/8/2009:  Price crossed above VWAP (0.3729).  Confirmed by volume.

Aradigm Corporation, a pharmaceutical company, engages in the development and commercialization of drugs delivered by inhalation for the treatment of respiratory diseases by pulmonologists in the United States. The company’s activities include partnered and self-initiated development programs addressing the treatment of cystic fibrosis, bronchiectasis, pulmonary arterial hypertension, chronic obstructive pulmonary disease (COPD), inhalation anthrax infections, and smoking cessation. Its proprietary product candidates under development include ARD-3100 under phase II clinical trial for the treatment of cystic fibrosis; ARD-3150 under phase II clinical trial for the treatment of bronchiectasis; ARD-1600 under phase I clinical trial for the treatment of tobacco smoking cessation; and ARD-1100, a preclinical product for the treatment of inhalation anthrax indications. The company’s collaborative product candidates comprise ARD-1550, a phase II product and ARD-1500, a preclinical stage product for the treatment of pulmonary arterial hypertension; and ARD-1700, a preclinical stage product for the treatment of asthma and COPD. Aradigm Corporation has a collaboration agreement with CyDex Pharmaceuticals, Inc. for the development and commercialization of products to deliver inhaled corticosteroids, anticholinergics, and beta-2 agonists for the treatment of asthma and COPD. The company was founded in 1991 and is based in Hayward, California.

ARDM at 9:50 AM 6/4/2009:  Crossed daily highs resistance.

Neoprobe Corporation, a biomedical company, develops and commercializes surgical and diagnostic products that enhance patient care by meeting the intraoperative diagnostic information needs of physicians and therapeutic treatment needs of patients. The company primarily offers a line of gamma radiation detection equipment used in the application of sentinel lymph node biopsy (SLNB), and a line of blood flow monitoring devices for various diagnostic and surgical applications. Its products include neoprobe GDS gamma detection system; and Quantix/OR, which is designed to permit cardiovascular surgeons to obtain intraoperative volume blood flow readings in various targeted blood vessels within seconds. The company also holds developmental and/or intellectual property rights related to two drugs can be used in connection with gamma detection devices in cancer surgeries. Its drugs under development include Lymphoseek, which determines the spread of solid tumor cancers into the lymphatic system; and RIGScan CR that enables surgeons to locate cancerous or disease involved tissue during colorectal cancer surgeries. The company was founded in 1983 and is based in Dublin, Ohio.

NEOP at 9:56 AM 6/2/2009:  Crossed daily highs resistance.

Unigene Laboratories, Inc., a biopharmaceutical company, engages in the research, production, and delivery of peptides for medical use primarily in the United States. The company focuses on the development of calcitonin and other peptide products for the treatment of osteoporosis and other indications, including nasal and oral calcitonin, and oral parathyroid hormone (PTH). It offers Fortical, a nasal calcitonin product for the treatment of postmenopausal osteoporosis. Unigene Laboratories has licensing agreements with GlaxoSmithKline to develop an oral formulation of an analog of PTH; Upsher-Smith Laboratories, Inc. to market Fortical; Novartis Pharma AG to manufacture calcitonin; and Shijiazhuang Pharmaceutical Group for research, development, and manufacture of recombinant salmon calcitonin and non-oral PTH. The company was founded in 1980 and is based in Boonton, New Jersey.

UGNE at 10:19 AM 6/1/2009:  Crossed daily highs resistance